Synthetic peptides for use in thrombus detection

• US 6,217,846 B1
• Filed: 01/21/1998
• Issued: 04/17/2001
• Est. Priority Date: 06/19/1989
• Status: Expired due to Fees

• Current Assignee: Antisoma Research Limited (Sarossa Plc)
• Original Assignee: Antisoma Research Limited (Sarossa Plc)
• Inventors: Stuttle, Alan William John
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/010,290
• Time in Patent Office: 1,182 Days
• Field of Search: 424/1.11, 424/1.65, 424/1.69, 424/9.1, 424/9.3, 424/9.4, 424/9.5, 530/300, 530/331, 534/7, 534/10-16
• US Class Current: 424/1.69
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61K 51/082 the peptide being a RGD-containing peptide
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 5/1019 with the first amino acid being basic
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Radioactively labeled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumor or CAM markers for the in vivo diagnosis and detection of thrombi, tumors or CAM in mammals.

Claims

1. A method for detecting a thrombus in a patient in vivo, which comprises the steps of administering to the patient a radiolabelled peptide which binds in vivo to arginine-glycine-aspartic acid binding sites on activated platelets in the thrombus, allowing the labelled peptide to bind to the RGD binding sites on the activated platelets in the thrombus and for the unbound peptide to clear systemically from the patient, and detecting the accumulated peptide.

2. The method of claim 1, wherein the radiolabelled peptide is labelled with a radioactive substance selected from the group consisting of ^99mTc, ¹²³I and ¹¹¹In.

3. The method of claim 1, wherein the radiolabelled peptide has 3 to 10 peptide units.

4. The method of claim 1, wherein the radiolabelled peptide is a synthetic peptide.